These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 12841679)

  • 1. Prognostic and predictive impact of NOTCH1 in early breast cancer.
    Engel J; Wieder V; Bauer M; Kaufhold S; Stückrath K; Wilke J; Hanf V; Uleer C; Lantzsch T; Peschel S; John J; Pöhler M; Weigert E; Bürrig KF; Buchmann J; Santos P; Kantelhardt EJ; Thomssen C; Vetter M
    Breast Cancer Res Treat; 2024 Aug; ():. PubMed ID: 39153127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biology of Metastasis With Focus on Proteases.
    Cufer T
    EJIFCC; 2005 May; 16(2):27-28. PubMed ID: 29942231
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients.
    Dovnik NF; Takac I
    Radiol Oncol; 2017 Mar; 51(1):65-73. PubMed ID: 28265234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.
    Lampelj M; Arko D; Cas-Sikosek N; Kavalar R; Ravnik M; Jezersek-Novakovic B; Dobnik S; Dovnik NF; Takac I
    Radiol Oncol; 2015 Dec; 49(4):357-64. PubMed ID: 26834522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX
    Aktas B; Bankfalvi A; Heubner M; Kimmig R; Kasimir-Bauer S
    Mol Clin Oncol; 2013 Nov; 1(6):1049-1054. PubMed ID: 24649291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects.
    Jing Y; Kovacs K; Kurisetty V; Jiang Z; Tsinoremas N; Merchan JR
    Mol Cancer Res; 2012 Oct; 10(10):1271-81. PubMed ID: 22912336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
    Kantelhardt EJ; Vetter M; Schmidt M; Veyret C; Augustin D; Hanf V; Meisner C; Paepke D; Schmitt M; Sweep F; von Minckwitz G; Martin PM; Jaenicke F; Thomssen C; Harbeck N
    BMC Cancer; 2011 Apr; 11():140. PubMed ID: 21496284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer.
    Harbeck N; Schmitt M; Vetter M; Krol J; Paepke D; Uhlig M; Paepke S; Jänicke F; Geurts-Moespot A; von Minckwitz G; Sweep F; Thomssen C
    Breast Care (Basel); 2008; 3(s2):11-15. PubMed ID: 20824008
    [No Abstract]   [Full Text] [Related]  

  • 9. High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.
    Smith R; Xue A; Gill A; Scarlett C; Saxby A; Clarkson A; Hugh T
    World J Surg; 2007 Mar; 31(3):493-502; discussion 503. PubMed ID: 17219285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
    Leissner P; Verjat T; Bachelot T; Paye M; Krause A; Puisieux A; Mougin B
    BMC Cancer; 2006 Aug; 6():216. PubMed ID: 16945123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis inhibitors found within the haemostasis pathway.
    Staton CA; Lewis CE
    J Cell Mol Med; 2005; 9(2):286-302. PubMed ID: 15963250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
    Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
    Br J Cancer; 1994 Feb; 69(2):398-405. PubMed ID: 8297742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
    Jelisavac-Cosic S; Sirotkovic-Skerlev M; Kulic A; Jakic-Razumovic J; Kovac Z; Vrbanec D
    Tumori; 2011; 97(4):532-9. PubMed ID: 21989445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
    Harbeck N; Kates RE; Schmitt M; Gauger K; Kiechle M; Janicke F; Thomassen C; Look MP; Foekens JA
    Clin Breast Cancer; 2004 Dec; 5(5):348-52. PubMed ID: 15585071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
    Gandolfo GM; Conti L; Vercillo M
    Anticancer Res; 1996; 16(4B):2155-9. PubMed ID: 8694536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer.
    Cufer T; Borstnar S; Vrhovec I
    Int J Biol Markers; 2003; 18(2):106-15. PubMed ID: 12841679
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.